Jefferies Group reissued their buy rating on shares of Alcobra Ltd. (NASDAQ:ADHD) in a report released on Wednesday morning. They currently have a $6.00 price objective on the stock.

Other analysts have also issued research reports about the company. Roth Capital set a $8.00 target price on Alcobra and gave the stock a buy rating in a research note on Saturday, October 1st. Cantor Fitzgerald restated a buy rating and set a $16.00 price target on shares of Alcobra in a research note on Thursday, September 29th. Goldman Sachs Group Inc. restated a buy rating on shares of Alcobra in a research note on Thursday, September 1st. Zacks Investment Research upgraded Alcobra from a hold rating to a buy rating and set a $2.25 price target on the stock in a research note on Tuesday, November 1st. Finally, Barclays PLC began coverage on Alcobra in a research note on Monday, August 1st. They set an equal weight rating and a $8.00 price target on the stock. One investment analyst has rated the stock with a sell rating, five have given a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of Hold and a consensus target price of $5.14.

Shares of Alcobra (NASDAQ:ADHD) traded up 2.03% on Wednesday, reaching $2.01. 104,102 shares of the company’s stock were exchanged. The stock’s market cap is $55.40 billion. Alcobra has a one year low of $1.77 and a one year high of $6.80. The company’s 50 day moving average is $2.29 and its 200-day moving average is $4.04.

Alcobra (NASDAQ:ADHD) last released its earnings results on Tuesday, November 15th. The company reported ($0.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.26) by $0.02. The business earned $7.90 million during the quarter, compared to analyst estimates of $4.30 million. On average, analysts anticipate that Alcobra will post ($0.93) EPS for the current year.

A number of large investors have recently modified their holdings of ADHD. KCG Holdings Inc. acquired a new stake in shares of Alcobra during the third quarter valued at $117,000. Credit Suisse AG increased its position in shares of Alcobra by 39.5% in the third quarter. Credit Suisse AG now owns 83,795 shares of the company’s stock worth $207,000 after buying an additional 23,717 shares during the last quarter. Stifel Financial Corp increased its position in shares of Alcobra by 34.2% in the second quarter. Stifel Financial Corp now owns 62,000 shares of the company’s stock worth $278,000 after buying an additional 15,800 shares during the last quarter. Jefferies Group LLC bought a new position in shares of Alcobra during the second quarter worth about $533,000. Finally, Palo Alto Investors LLC increased its position in shares of Alcobra by 7.3% in the second quarter. Palo Alto Investors LLC now owns 272,788 shares of the company’s stock worth $1,225,000 after buying an additional 18,600 shares during the last quarter. 73.72% of the stock is owned by institutional investors and hedge funds.

About Alcobra

Alcobra Ltd is an Israel-based Biopharmaceutical company. It focuses on the development and commercialization of a proprietary drug, MG01CI, to treat Attention Deficit Hyperactivity Disorder (ADHD), a common and morbid neuropsychiatric condition in children and adults. Adult ADHD is associated with increased health risks and healthcare costs, higher divorce rates, lower levels of socioeconomic attainment, lower academic achievement, unemployment and work place deficits, increased risks for motor vehicle accidents, greater likelihood of additional psychiatric disorders, increased criminal activity and incarceration, and higher rates of substance use and abuse.

5 Day Chart for NASDAQ:ADHD

Receive News & Stock Ratings for Alcobra Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alcobra Ltd. and related stocks with our FREE daily email newsletter.